Ajanta Pharma Limited
Ajanta Pharma Limited is a Public Non-govt company company incorporated in 1979 and based in Maharashtra, India. Ajanta Pharma Limited operates in Manufacture of pharmaceuticals, medicinal chemicals and botanical products (NIC 24230) with authorized capital of ₹30.00 Cr and paid-up capital of ₹25.63 Cr. For 2016-17, the company reported revenue of ₹1889.66 Cr and profit after tax of ₹499.81 Cr. RegisterKaro's Compliance Health Score for the company is 35/100 (grade F), reflecting a weak compliance posture.
Ajanta Pharma - Manufacturer of branded and generic pharmaceutical products across multiple therapeutic areas. Public Company. Raised funding from 1 investor.
Quick facts
Directors
LockedDirectors, DINs & appointment history for Ajanta Pharma Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
MCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 23 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 24 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | +16d | filed |
| MGT-7 | FY2022-23 | 25 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Ajanta Pharma Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 284299984 | Kotak Mahindra Bank Ltd(Bank) | ₹4.13 Cr | 27 Jan 2020 | Satisfied |
| 532332309 | ICICI Bank Ltd(Bank) | ₹14.12 Cr | 19 Sep 2021 | Satisfied |
| 946479587 | HDFC Bank Ltd(Bank) | ₹16.17 Cr | 27 Jan 2020 | Open |
| 188430839 | HDFC Bank Ltd(Bank) | ₹20.03 Cr | 04 Jul 2019 | Satisfied |
Charge IDs, lenders & amounts for Ajanta Pharma Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2016-17 | — | ||||
| 2014-15 | — |
Detailed Financials
2 FYs| Line item | 2016-17 | 2014-15 |
|---|---|---|
| Income statement | ||
| Revenue from operations | ||
| Other income | ||
| Total income | ||
| Total expenses | ||
| Profit before tax | ||
| Profit / (Loss) after tax | ||
| Balance sheet | ||
| Equity / Net worth | ||
| Borrowings | ||
| Current liabilities | ||
| Total liabilities | ||
| Current assets | ||
| Cash & equivalents | ||
| Total assets | ||
| Employees | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2016-17 | +31.0% | — | — | |
| Profit after Tax2016-17 | +84.0% | — | — | |
| Net Worth2016-17 | +40.0% | — | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2014-15 | +22.04% | — | +38.96% | +28.21% | — | |||
| 2016-17 | +26.45% | +35.96% | +33.23% | +28.98% | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 2 | 1,32,67,783 | 69.94% |
| Institutional Investors | 1 | 8,47,551 | 4.47% |
| Public & Others | 43 | 48,54,057 | 25.59% |
Promoter, institutional & public holding for Ajanta Pharma Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
9 peersTop 7 in Manufacture of pharmaceuticals, medicinal chemicals and botanical products
by healthView all ›Events & timeline
2External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.